Introduction {#section5-1756287219870412}
============

Urinary lithiasis is a highly prevalent condition, affecting approximately 11% of the world's population and there is evidence of increment in incidence over the last decades.^[@bibr1-1756287219870412][@bibr2-1756287219870412][@bibr3-1756287219870412]--[@bibr4-1756287219870412]^ Stone disease is a chronic disease characterized by high recurrence rates that affects mostly young adults; however, it can present at any age.^[@bibr3-1756287219870412],[@bibr5-1756287219870412]^

The elderly population is increasing very fast. It is estimated that by 2050 there will be twice as many individuals older than 65 years than in 2015.^[@bibr6-1756287219870412]^ Along with the change in global age distribution, an increment in the incidence of urinary lithiasis in elderly patients can also be observed.^[@bibr7-1756287219870412]^ Stone disease prevalence in the elderly increased from 2% to 10% between 1980 and 2000.^[@bibr1-1756287219870412],[@bibr8-1756287219870412],[@bibr9-1756287219870412]^ This particular population has a higher comorbidity burden, which may lead to greater frailty and decline in their physical and cognitive functions.^[@bibr10-1756287219870412]^ In addition to that, polypharmacy is extremely frequent in the elderly and may lead to additional risks.^[@bibr11-1756287219870412]^ Over the last decades, minimally invasive technologies have been proposed to increase the safety and effectiveness of urinary stone disease management. Extracorporeal shockwave lithotripsy (ESWL) was first used to treat renal calculi in 1980 and has become widely popular since then.[@bibr12-1756287219870412] Currently, ESWL is one of the first-line options for the treatment of renal and ureteral calculi,^[@bibr13-1756287219870412],[@bibr14-1756287219870412]^ although ureteroscopy has been progressively more frequent in recent decades.^[@bibr13-1756287219870412][@bibr14-1756287219870412]--[@bibr15-1756287219870412]^ For young individuals, treatment of even asymptomatic stones is often indicated due to the high risk of symptoms or complications. However, there is a paucity of data in the literature, and no current guidelines or standardization regarding urinary stone disease treatment in the elderly population have been proposed.^[@bibr16-1756287219870412]^ The aim of the present study was to assess the characteristics of older adults (\>75 years old) treated with ESWL in a very large volume center. As secondary objectives, we will also describe the complications and mortality rates after this procedure in octogenarians.

Materials and methods {#section6-1756287219870412}
=====================

Records of all ESWL procedures performed at the Center of Renal Calculus Treatment of Hospital São Luiz Jabaquara from 1998 to 2015 were evaluated. During this period, 54,298 treatments were performed in 33,938 patients. Patients were referred for ESWL by 2056 different urologists. Our institution is a tertiary center that receives the patients undergoing ESWL sessions; however, the referring urologists are usually responsible for the postprocedure follow up. We evaluated all patients older than 75 years who underwent ESWL during this period. Among these patients, we performed additional analysis on the subset of octogenarians. All patients aged more than 80 years were additionally evaluated, and these patients or their caregivers were invited to participate in the present study. Those who accepted had their charts reviewed and were interviewed by telephone.

All patients were treated under the same protocol, which includes venous sedation performed by an anesthesiologist who accompanied the patient during and after the procedure. Treatments were performed according to the protocol established by the institution. From 1998 to 2003, we used the Dornier MPL9000; from 2003 to 2013 the Dornier Doli S; from 2007 to 2015 the Dornier Compact Sigma; and from 2013 to 2015 we also used the Dornier Gemini (Dornier MedTech, Wessling, Germany). An outpatient treatment scheme was adopted. Data from these patients were organized in a database with the following variables: sex, age, laterality, stone location (such as upper, middle, or lower calyx groups; renal pelvis; ureter; or bladder), number of shock waves, stone size, and type of application (first application or reapplication). Data related to patient deaths (date, cause of death) were additionally reviewed at the Mortality Information Improvement Program of the Muni-cipality of São Paulo (PROAIM-SP), as a 'double check' procedure for all patients. Continue and categorical variables were presented as mean, standard deviation (SD) and frequencies, percentages (%), respectively. Complications were classified according to Clavien--Dindo classification.^[@bibr17-1756287219870412]^ Statistical analysis was performed using Stata/IC 12.0. Student's *t*-test was used to compare means and the chi-square test was applied for frequency comparison between groups; *p* \< 0.05 was established as statistically significant. The present study was approved by the institutional review board (Process 935.640-9-26-2014).

Results {#section7-1756287219870412}
=======

Among the 33,938 patients undergoing ESWL at our institution in this period, 602 ESWL procedures were performed in 371 patients older than 75 years. Baseline characteristics variables are presented in [Table 1](#table1-1756287219870412){ref-type="table"}.

###### 

Demographic characteristics of all patients and clinical information of the urinary calculi.

![](10.1177_1756287219870412-table1)

  --------------------------------------------------------------------
                           ⩾75 year\        \<75 year\       *p*
                           (*n* = 371)      (*n* = 33,464)   
  ------------------------ ---------------- ---------------- ---------
  **Age** (years)          78 (75--90)      42.1 (3--74)     \<0.001

  **Number of sessions**   604              53,542           

  **Gender**                                                 0.915

  Male                     53 (55.2%)       19,043 (56.3%)   

  Female                   43 (44.8%)       14,799 (43.7%)   

  **Side**                                                   0.036

  Right                    273 (45.2%)      26,533 (49.6%)   

  Left                     331 (54.8%)      27,009 (50.4%)   

  **Application**                                            \<0.001

  First                    502 (83.1%)      47,366 (88.5%)   

  Reapplication            102 (16.9%)      6176 (11.5%)     

  **Shockwaves**                                             0.58

  Mean (SD)                2688.5 (779.1)   2650.8 (919.9)   

  **Size** (mm)                                              \<0.001

  Mean (SD)                10.1 (4.48)      8.5 (4.0)        

  **Topography**                                             0.98

  Renal                    517 (85.6%)      46,866 (87.5%)   

  Ureteral                 72 (11.2%)       6542 (12.2%)     

  Bladder                  15 (0.2%)        127 (0.3%)       
  --------------------------------------------------------------------

SD, standard deviation.

We also analyzed the 96 octogenarians in our cohort, corresponding to 0.28% of the total. [Figure 1](#fig1-1756287219870412){ref-type="fig"} shows the age distribution of patients undergoing ESWL at our institution. The mean age of the octogenarians was 82.7 (80--90) years; 43 patients were female and 53 were male. Mean stone size for this subgroup was 10.21 mm (3--30 mm). Most calculi were located at the kidney. Mean number of shock waves per session was 2605, yet this varies according to the observation of real-time stone fragmentation.

![Distribution of 33,938 patients who underwent ESWL according to age group.\
ESWL, extracorporeal shockwave lithotripsy.](10.1177_1756287219870412-fig1){#fig1-1756287219870412}

Of the 96 octogenarians in our cohort, we were able to interview 45 patients or caregivers; 14 had died and information was obtained from the municipality information service (PROAIM-SP), and 2 refused to participate. The 45 octogenarians who answered the questionnaires underwent a total of 66 ESWL sessions. We were not able to obtain information about the remaining 35 octogenarians.

Five octogenarians had already passed away when the questionnaire was applied and four were alive at the time of the interview, but died after that. Additionally, 14 patients had their mortality data obtained from PROAIM-SP (23/47 patients). Mean interval between ESWL treatment and death was 53 months. The main causes of death were malignancies (eight patients) followed by cardiovascular disease (five patients). [Figure 2](#fig2-1756287219870412){ref-type="fig"} shows the Kaplan--Meyer's survival curve of octogenarians after the ESWL procedure.

![Kaplan--Meyer's survival curve of octogenarians who underwent ESWL.\
ESWL, extracorporeal shockwave lithotripsy.](10.1177_1756287219870412-fig2){#fig2-1756287219870412}

The most common comorbidities among octogenarians were systemic arterial hypertension (66.67%) and dyslipidemia (26.67%). Most commonly used medications within this group were antihypertensives (66.67%) and lipid-lowering agents (28.89%); 19 patients were using two or more drugs when treated with ESWL.

No intraoperative complications were seen during the procedures, and none of the procedures had to be cancelled. Postoperative complications included one patient with macroscopic hematuria and three patients required ancillary stone-clearing procedures (6.6%). Obstructive pyelonephritis occurred in one man who was treated successfully after ureteral stent placement and intravenous antibiotics. Another patient underwent ureteroscopy to remove an obstructive ureteral stone, and a third patient with a 3-cm kidney stone underwent percutaneous nephrolithotripsy as definitive treatment.

Prevalence of comorbidities, age-adjusted Charlson comorbidity index (CCI), medications used by these patients, Clavien-Dindo classification, interval between ESWL session and death, and death causes are shown in [Table 2](#table2-1756287219870412){ref-type="table"}.

###### 

Death causes, comorbidities, CCI, medications used and complications of ESWL according to Clavien--Dindo index among octogenarians.

![](10.1177_1756287219870412-table2)

  Cause of death                   *n*                              Mean interval between treatment and death (months)   
  -------------------------------- -------------------------------- ---------------------------------------------------- ---------
  Malignancies                     8                                53                                                   
  Cardiovascular                   5                                44                                                   
  Lung                             3                                61                                                   
  Stroke                           2                                114                                                  
  Others                           2                                87                                                   
  Unknown                          3                                52                                                   
  **Comorbidities**                ***n* (%)**                                                                           
  Cardiopathy                      11 (24.4%)                                                                            
  Pneumopathy                      4 (8.9%)                                                                              
  Arterial Hypertension            30 (66.7%)                                                                            
  Malignancies                     5 (11.1%)                                                                             
  Prostate Pathologies             6 (25% of men)                                                                        
  Neurological Pathologies         10 (22.2%)                                                                            
  Bone Pathologies                 10 (22.2%)                                                                            
  Dyslipidemia                     12 (26.7%)                                                                            
  Diabetes                         8 (18.2%)                                                                             
  **CCI**                          ***n* (%)**                      **Clavien-Dindo**                                    ***n***
  3                                21 (47.7%)                       I                                                    1
  4                                10 (22.7%)                       II                                                   0
  5                                6 (13.6%)                        IIIA                                                 3
  6                                6 (13.6%)                        IIIB                                                 0
  7                                1 (2.3%)                         IVA                                                  0
  **Medications**                  ***n* (%)**                                                                           
  Antihypertensive                 30 (66.7%)                                                                            
  Antidiabetic                     9 (20.0%)                                                                             
  Hypolipemiant                    13 (28.9%)                                                                            
  Insulin                          0                                                                                     
  Antiplatelet                     8 (17.8%)                                                                             
  Prostate                         3 (12.5% of men -- 6.7% total)                                                        
  Anticoagulants                   1 (2.2%)                                                                              
  Neurological                     7 (15.6%)                                                                             
  Supplements                      5 (11.1%)                                                                             
  Antiarrhythimic or Cardiologic   3 (6.8%)                                                                              

CCI,Charlson comorbidity index; ESWL, extracorporeal shockwave lithotripsy.

Discussion {#section8-1756287219870412}
==========

Studies analyzing trends in urinary lithiasis incidence have observed that the elderly population represents 12% of cases. In this group of patients, 40% presented their first calculus before the age of 50, and 10% were diagnosed with urinary calculus for the first time after the age of 70.^[@bibr6-1756287219870412]^ In Japan, the country with the oldest population in the world, a study published by Yasui and colleagues showed an increase in the incidence of urinary lithiasis among octogenarians, from 21 × 10^−5^ in men and 3.6 × 10^−5^ in women in 1965 to 113.5 × 10^−5^ in men and 62.9 × 10^−5^ in women in 2005. These data demonstrate that urinary stone disease has become a more relevant condition in older individuals as it can interfere with quality of life and bear complications.^[@bibr7-1756287219870412]^ Additionally, it is well known that urinary lithiasis represents an important economic burden.^[@bibr18-1756287219870412],[@bibr19-1756287219870412]^ For elderly patients, these costs might be even higher, as they normally present higher rates of hospitalization and longer length of hospital stay. Expenses with patients aged 65 years or older in Medicare in the United States have increased 36%, from \$613 million in 1992 to \$834 million in 1998.^[@bibr5-1756287219870412]^

Our study has some important findings. First, we observed that the subgroup of very elderly patients (\>75 years) had larger stones and more retreatments than the younger group. Nevertheless, we observed that demographics and specific characteristics of the treatment (gender distribution, mean stone size, laterality, reapplications, number of shock waves and topography within the upper urinary tract) were similar between octogenarians and patients younger than 80 years old who underwent ESWL during the same period ([Table 1](#table1-1756287219870412){ref-type="table"}). Larger stones and more frequent additional repeated procedures were probably a consequence of the intention to avoid the greater surgical and anesthetic risks of endoscopic or open surgical treatments. Our cohort of 33,938 patients were treated by 2056 different urologists. Therefore, we believe our cohort to be a good reflection of current practice patterns in a nonacademic setting.

Before the development of minimally invasive techniques for the treatment of renal calculi, many elderly patients were no longer treated because of the great risk of open surgery, which could present a greater risk than the calculus itself. However, ESWL represented a good treatment alternative when it was introduced as an option for stone disease management. Studies evaluating the efficacy of ESWL treatment for elderly patients suggested worst outcomes for this group of patients. In a multivariate analysis, Ng and colleagues demonstrated that kidney stone free rate (SFR) is lower in older patients when compared with patients under 40 years of age *versus* 40--60 years *versus* 60 years and older (54%, 43%, and 37.6%, respectively).^[@bibr20-1756287219870412]^ SFR for ESWL in patients older than 70 years has been reported to be between 52.1 and 63.5%.^[@bibr21-1756287219870412],[@bibr22-1756287219870412]^ These results are worse than those reported by Simunovic and colleagues, who reported SFR of 67.98% for patients over 60 years of age. These rates are significantly lower than the overall SFR of 80.95% at Simunovic's institution.^[@bibr23-1756287219870412]^ A considerable number of studies have suggested that ESWL is less effective in elderly patients, and many have found similar results for younger *versus* elderly patients.^[@bibr22-1756287219870412],[@bibr24-1756287219870412][@bibr25-1756287219870412]--[@bibr26-1756287219870412]^ The mechanism that may explain worse outcomes in the elderly is not fully understood, but it is believed that senile physiological changes, such as sclerotic alterations of the renal parenchyma and lower glomerular filtration rate, contribute to these findings.^[@bibr27-1756287219870412]^ ESWL is still the one of the first treatment options for small kidney stones and proximal ureteral stones.^[@bibr28-1756287219870412]^

Second, we observed no severe complications during the procedures. No procedure was interrupted for any immediate complications, and postoperative complications were not common. All postoperative complications were easily managed. There was one patient with a minor complication, which was macroscopic hematuria with resolution after clinical observation. Another patient presented an obstructive pyelonephritis secondary to stone migration, which was treated successfully after ureteral stent placement and administration of intravenous antibiotic. Ureteroscopy as an auxiliary procedure was necessary in two patients, and another one patient underwent percutaneous nephrolithotripsy due to failure of the ESWL. Consistent with previous reports, there were no serious complications in our series, suggesting shock waves to be safe in the treatment of older patients with urinary stone disease.^[@bibr21-1756287219870412][@bibr22-1756287219870412]--[@bibr23-1756287219870412],[@bibr26-1756287219870412],[@bibr29-1756287219870412]^

Moreover, octogenarians treated in our cohort may benefit from a longer life expectancy if ESWL procedures were performed. Even though 38.9% of the patients passed away during the study period, mortality occurred, on average, 4.38 years after the ESWL treatment session. Only one patient died within the first year following treatment. Additionally, the causes of death were not associated with lithiasis or ESWL ([Table 2](#table2-1756287219870412){ref-type="table"}), which reinforces the safety of ESWL in this population. ESWL is a relatively simple and low-risk procedure, and can prevent the acute manifestation/complications that may predispose this elderly population to longer hospitalization times, and more antibiotics.^[@bibr19-1756287219870412]^

As expected, the comorbidity burden was higher in this group, with hypertension being the most prevalent (66.7%), followed by dyslipidemia (26.7%), heart disease (24.4%), and diabetes (18.2%). Most patients had a CCI of 3 or 4. Only one patient had CCI 7. These comorbidities, however, brought little interference to other treatments. Only one patient was required to interrupt acetylsalicylic acid prior to ESWL treatment, and, as previously stated, no ESWL session was interrupted.

The present study has some limitations. It was retrospective in its design, with a relatively low number of patients. However, there are no other studies in the literature specifically evaluating very elderly patients, and, besides, this is a rare population (only 1.1% of all patients treated in our series). Another limitation was the high rates of patients lost to follow up. Nonetheless, data obtained from PROAIM provided precise information on mortality, so we could be assured that uncontacted patients had not died. We evaluated patients after a long follow-up period, with a mean of 6.22 years. The most important limitation is the lack of information about the results, which does not allow us to draw conclusions regarding the efficacy of ESWL in this population. However, studies evaluating ESWL efficacy in elderly patients have been published.^[@bibr20-1756287219870412],[@bibr21-1756287219870412],[@bibr23-1756287219870412][@bibr24-1756287219870412][@bibr25-1756287219870412]--[@bibr26-1756287219870412]^ Prospective and controlled studies are warranted to confirm our findings.

Conclusion {#section9-1756287219870412}
==========

In conclusion, ESWL has been used by urologists for the treatment of uncomplicated urinary stone disease in elderly patients despite the suggested changes associated with aging and high burden of comorbidities. ESWL was indicated and performed in a similar way as for younger populations, except for larger stones that needed additional sessions. The complication profile seemed similar to that in the general population. Octogenarians undergoing ESWL may have some survival benefit, justifying active treatment in this population.
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